Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2021 - Opportunities And Strategies, Market Forecast And Trends

The G-CSF (Granulocyte Colony Stimulating Factors) market consists of sales of G-CSF drugs and relates services. Granulocyte colony-stimulating factor is a drug used to treat neutropenia, a disorder in which there is a lower-than-average number of white blood cells, caused by certain forms of chemotherapy.

Global G-CSF (Granulocyte Colony Stimulating Factors) Market Size And Drivers:

The global Granulocyte-Colony Stimulating Factor (G-CSF) Market declined from $7.30 billion in 2019 to $6.91 billion in 2020 at a compound annual growth rate (CAGR) of -5.27%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $8.33 billion in 2023 at a CAGR of 6.44%. The increasing prevalence of cancer is a key factor driving the growth of the G-CSF market.

Request For A Sample For The Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp

Trends In The Global G-CSF (Granulocyte Colony Stimulating Factors) Market

The increasing demand for prophylaxis G-CSF is another key factor driving the growth of the granulocyte-colony stimulating factor market. The prophylaxis with G-CSF decreases the occurrence of febrile neutropenia (FN), allowing patients to receive and stay on myelosuppressive chemotherapy. The current use of G-CSF prophylaxis offers significant benefits including reducing incidents of febrile neutropenia by 3.3 million and cases of chemotherapy reduced dosage intensity by less than 85%, over the next 10 years.

Global G-CSF (Granulocyte Colony Stimulating Factors) Market Segments:

The global G-CSF market is further segmented based on type, application and geography.
By Type: Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Accofil), Long acting (pegylated) filgrastim (pegfilgrastim, Neulasta, Pelmeg, Ziextenco), Lipegfilgrastim (Lonquex).
By Application: Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic and Autoimmune Disorders, Others.
By Geography: The global granulocyte colony stimulating factors market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, the North American was the largest region in the G-CSF market.

Read More On The Report For The Global G-CSF (Granulocyte Colony Stimulating Factors) Market At:
https://www.thebusinessresearchcompany.com/report/g-csf-granulocyte-colony-stimulating-factors-global-market-report-2020-30-covid-19-growth-and-change

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides g-CSF (granulocyte colony stimulating factors) market overviews, analyzes and forecasts market size and growth for the global g-CSF (granulocyte colony stimulating factors) market, g-CSF (granulocyte colony stimulating factors) market share, g-CSF (granulocyte colony stimulating factors) market players, g-CSF (granulocyte colony stimulating factors) market segments and geographies, g-CSF (granulocyte colony stimulating factors) market’s leading competitors’ revenues, profiles and market shares. The g-CSF (granulocyte colony stimulating factors) market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.